Ligand Independence of the T618I Mutation in the Colony-stimulating Factor 3 Receptor (CSF3R) Protein Results from Loss of O-Linked Glycosylation and Increased Receptor Dimerizatio...

Por Maxson, Julia E., Luty, Samuel B., MacManiman, Jason D., Abel, Melissa L., Druker, Brian J., Tyner, Jeffrey W.
Publicado em 2014

Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML

Por Agarwal, Anupriya, Fleischman, Angela G., Petersen, Curtis L., MacKenzie, Ryan, Luty, Samuel, Loriaux, Marc, Druker, Brian J., Woltjer, Randall L., Deininger, Michael W.
Publicado em 2012

Characterization of the leukemogenic potential of distal cytoplasmic CSF3R truncation and missense mutations

Por Zhang, Haijiao, Schultz, Anna Reister, Luty, Samuel, Rofelty, Angela, Su, Yulong, Means, Sophie, Bottomly, Daniel, Wilmot, Beth, McWeeney, Shannon K., Tyner, Jeffrey W.
Publicado no Leukemia (2017)

Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets

Por Kanojia, Deepika, Garg, Manoj, Martinez, Jacqueline, M.T., Anand, Luty, Samuel B., Doan, Ngan B., Said, Jonathan W., Forscher, Charles, Tyner, Jeffrey W., Koeffler, H. Phillip
Publicado no J Hematol Oncol (2017)

JAK2(V617I) results in cytokine hypersensitivity without causing an overt myeloproliferative disorder in a mouse transduction-transplantation model

Por Brooks, Stefan A., Luty, Samuel B., Lai, Hew Yeng, Morse, Sarah J., Nguyen, Thanh Kim, Royer, Lacey R., Agarwal, Anupriya, Druker, Brian J., Fleischman, Angela G.
Publicado no Exp Hematol (2015)

The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition

Por Fleischman, Angela G., Maxson, Julia E., Luty, Samuel B., Agarwal, Anupriya, Royer, Lacey R., Abel, Melissa L., MacManiman, Jason D., Loriaux, Marc M., Druker, Brian J., Tyner, Jeffrey W.
Publicado em 2013

Therapeutically targetable ALK mutations in leukemia

Por Maxson, Julia E., Davare, Monika A., Luty, Samuel B., Eide, Christopher A., Chang, Bill H., Loriaux, Marc M., Tognon, Cristina E., Bottomly, Daniel, Wilmot, Beth, McWeeney, Shannon K., Druker, Brian J., Tyner, Jeffrey W.
Publicado no Cancer Res (2015)

The Colony Stimulating Factor 3 Receptor T640N mutation is oncogenic, sensitive to JAK inhibition, and mimics T618I

Por Maxson, Julia E., Luty, Samuel B., MacManiman, Jason D., Paik, Jason C., Gotlib, Jason, Greenberg, Peter, Bahamadi, Swaleh, Savage, Samantha L., Abel, Melissa L., Eide, Christopher A., Loriaux, Marc M., Stevens, Emily A., Tyner, Jeffrey W.
Publicado no Clin Cancer Res (2015)

Identification and characterization of Tyrosine Kinase Non-receptor 2 mutations in leukemia through integration of kinase inhibitor screening and genomic analysis

Por Maxson, Julia E., Abel, Melissa L., Wang, Jinhua, Deng, Xianming, Reckel, Sina, Luty, Samuel B., Sun, Huahang, Gorenstein, Julie, Hughes, Seamus, Bottomly, Daniel, Wilmot, Beth, McWeeney, Shannon K., Radich, Jerald, Hantschel, Oliver, Middleton, Richard E, Gray, Nathanael S., Druker, Brian J., Tyner, Jeffrey W.
Publicado no Cancer Res (2015)

TNFα facilitates clonal expansion of JAK2(V617F) positive cells in myeloproliferative neoplasms

Por Fleischman, Angela G., Aichberger, Karl J., Luty, Samuel B., Bumm, Thomas G., Petersen, Curtis L., Doratotaj, Shirin, Vasudevan, Kavin B., LaTocha, Dorian H., Yang, Fei, Press, Richard D., Loriaux, Marc M., Pahl, Heike L., Silver, Richard T., Agarwal, Anupriya, O'Hare, Thomas, Druker, Brian J., Bagby, Grover C., Deininger, Michael W.
Publicado em 2011